Nicotine Lozenge vs Tablet: Which Is Faster?

If you came from a 2mg or 4mg lozenge, this is the comparison that actually has data. A nicotine lozenge is parked in the mouth and dissolves over 20 to 30 minutes, while a sublingual nicotine tablet melts under the tongue. Most "vs" pages in this category borrow numbers from different papers and hope you do not notice. This one does not have to.

Rose, J.E., and colleagues published the only head-to-head blood study of BRST in *Psychopharmacology* in 2022. They put a 2mg sublingual tablet against a 2mg Commit lozenge in the same smokers. Peak time was 14 minutes versus 82.5 minutes, and peak height was similar at 4.4 versus 5.3 ng/mL: same dose, same people, different route.

That is the whole argument in one trial: the lozenge is not weak, it is late. This page walks the study the way a reporter would (who ran it, how many people, what they measured, what the numbers can and cannot say), then a table, then where other lozenge papers sit as class context.BRSTis a 2mg peppermint melt. A Commit or Nicorette lozenge is the slow park.

Two products, one published trial

A classic nicotine lozenge is buccal and slow on purpose. You park it, you move it from side to side, you do not chew it, and you wait. The nicotine is bound in a polacrilex matrix, the same family as gum, and it is meant to trickle through cheek tissue over a long sit. That is a real product with a real job. Plenty of adults want something that lasts half an hour.

A BRST melt is sublingual and fast on purpose. You place it under the tongue, back toward the molars, and you keep still for about five minutes. Ten ingredients, made in a US facility, no spit, and nothing to park in the cheek while a meeting runs long. The product is the early rise, not a bigger number on a tin.

Those are different jobs that happen to share a mouth. The only published blood comparison we have for this tablet is versus that 2mg lozenge. It is not versus gum, not versus a pouch, not versus a 4mg lozenge. Rose is a lozenge comparison, not a pouch comparison. For the other parked formats, seenicotine tablet vs gumandnicotine tablet vs pouch. The full format map istablet vs gum, lozenge, and pouch.

Who ran the study, and what they measured

Jed E. Rose is a nicotine researcher. In 2022 he and his co-authors (Behm, Botts, Botts, Willette, Vocci, and McCarty) published "Novel rapid-acting sublingual nicotine tablet as a cigarette substitution strategy." That title is the authors' frame. The paper is still the receipt for how this 2mg tablet behaves next to a 2mg lozenge.

There were two arms.

The pharmacokinetic arm enrolled six smokers. Each person used both products, a classic crossover, so the comparison is within the same bodies. The labeled dose was 2mg either way. The researchers drew venous blood and watched nicotine rise and fall. The questions were simple: how fast does it peak, how high does it go, how much total nicotine shows up over time, and does anything happen in the first four minutes.

The subjective arm enrolled twenty-four smokers after two hours without nicotine, with no placebo. This arm did not measure blood. It asked people how they felt: craving on a 0 to 4 scale, craving relief on a 1 to 7 scale against their usual cigarette, and heart rate as a blunt physical check. Small sample, no dummy tablet, and still the only published feel data on this exact 2mg melt.

The methods and figures live onBRST pharmacokinetics. This page is the comparison, not a second recap of every chart.

What the blood data showed

Time to peak, often written Tmax, is the clock. In six smokers, the 2mg tablet peaked at 14 minutes. The 2mg Commit lozenge peaked at 82.5 minutes. That is not a rounding error. It is the difference between a rise you notice and a lozenge that is still getting started when the tablet is already coming down the other side.

The first four minutes make the same point in a smaller window. On the tablet, venous nicotine rose at 0.4 ng/mL per minute. On the lozenge, the rate was 0.0. The lozenge had not produced a measurable rise yet. The authors also noted that the tablet reached about half of its eventual peak inside those four minutes. If you have ever parked a lozenge and wondered when it would start, that is the interval you were sitting in.

Peak height, Cmax, is a different question. The tablet reached 4.4 ng/mL and the lozenge reached 5.3 ng/mL, which are in the same neighborhood. Faster did not mean a higher spike. Anyone who says BRST "hits harder than a lozenge" on peak concentration is not reading the paper; it hits earlier.

Total exposure, AUC, ran the other way. The tablet's area under the curve was 949.5 ng·min/mL. The lozenge's was 1189.9. The authors' read is the honest one: a fast-disintegrating tablet loses some nicotine to swallowing, and swallowed nicotine is metabolized in the liver before it counts. Speed won the early window. The lozenge won the long total. That is a route finding, not a "stronger than a lozenge" claim.

The table is a summary of the paragraphs above, not a substitute for them. Charts and methods:BRST pharmacokinetics. The route itself:how sublingual delivery worksandthe science of nicotine absorption.

What people reported at five minutes

Twenty-four smokers, two hours without nicotine, no dummy tablet. Craving on a 0 to 4 scale went from 2.6 to 1.0 at five minutes. That is a rating drop on this tablet, in this arm, with no placebo.

Participants also scored craving relief against their usual cigarette on a 1 to 7 scale: the tablet scored 4.2 and the cigarette scored 4.6. They scored the tablet 4.2 and their usual cigarette 4.6.

Heart rate moved from 67.8 to 76.2 beats per minute. Nicotine does that. It is a physical sign that something reached circulation, not a wellness metric.

The blood arm was six people. The comparator was one 2mg lozenge.

Where other lozenge studies sit

Rose is the BRST paper. Choi and Azzopardi are the class.

Choi, Dresler, Norton, and Strahs (2003) compared nicotine polacrilex lozenges with same-dose gum. Lozenges ran 8 to 10 percent higher on peak concentration and 25 to 27 percent higher on total exposure, because a gum retains residual nicotine in the chewed wad and a lozenge does not. You dissolve the whole unit, so more of the labeled milligrams leave the product, and time to peak still sat in the slow-oral band. A lozenge can beat gum on how much nicotine you get. It does not, in that paper, become a fast product.

Azzopardi et al. (2022) put a 4mg Nicorette mini-lozenge at a median 60 minutes and 8.3 ng/mL, next to 4mg chew-and-park gum at 4.4 ng/mL and 50 minutes. So a 4mg lozenge can out-peak a 2mg tablet on height. It does not outrun 14 minutes. If you want the hour-long dissolve and the higher labeled milligram, use a lozenge as labeled. If you want the early rise, use the melt.

Those two papers are not BRST trials. They tell you what the lozenge class does when nobody from this company is in the room.

How you use a lozenge vs how you use a melt

A lozenge you park and wait. You move it side to side. You do not chew it. Sit time is often 20 to 30 minutes, sometimes longer. Swallowing too much saliva loaded with nicotine is how people get hiccups.

A melt you place and leave: under the tongue, back near the molars, still for about five minutes. Do not chew it, park it in the cheek like a mini lozenge, or spit, and skip food and drink while it sits. The tablet is designed to break down fast. Stillness is what keeps the dose on the thin tissue instead of washing it into the gut.

If you like the lozenge schedule, stay on the lozenge. If the wait is the product, the melt is the format change. Adults who want the early rise cantry BRST 2mg melts. One tablet is one 2mg melt.

The format word itself, including Microtab and Rogue, is onnicotine tablets. Pouch shoppers:nicotine tablet vs pouchandBRST vs Zyn.

Frequently asked questions

Is a nicotine tablet just a small lozenge?

No. A lozenge is buccal and slow. BRST is sublingual and fast. Rose 2022 is the receipt.

Why was peak concentration slightly lower on BRST?

4.4 versus 5.3 ng/mL. Similar peaks. The tablet's total exposure was lower. Rose suggested swallowed nicotine. The product is built for time to peak, not for winning a six-hour total-exposure contest.

Did Rose compare BRST to gum or Zyn?

No. Only the 2mg lozenge. Gum and pouch numbers on this site come from those products' own papers.

Does faster time to peak mean BRST is stronger?

No. Peak height was similar. Total exposure was lower on the tablet. Faster is the claim. Stronger is not.

Is BRST FDA-approved to replace a lozenge?

No. Nicorette and Commit lozenges are. BRST is an adult nicotine product.

Sources

• Rose, J.E., Behm, F.M., Botts, T.L., Botts, D.R., Willette, P.N., Vocci, F., & McCarty, J. (2022). Novel rapid-acting sublingual nicotine tablet as a cigarette substitution strategy. *Psychopharmacology* 239, 2853–2862. https://doi.org/10.1007/s00213-022-06171-z

• Choi, J.H., Dresler, C.M., Norton, M.R., & Strahs, K.R. (2003). Pharmacokinetics of a nicotine polacrilex lozenge. *Nicotine & Tobacco Research* 5(5), 635–644. https://pubmed.ncbi.nlm.nih.gov/14577980/

• Azzopardi, D., Ebajemito, J., McEwan, M., et al. (2022). A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products. *Scientific Reports* 12, 6949. https://doi.org/10.1038/s41598-022-10544-x